Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s share price traded down 4.8% during trading on Wednesday following insider selling activity. The stock traded as low as $22.22 and last traded at $22.1740. Approximately 1,743,679 shares were traded during mid-day trading, a decline of 60% from the average session volume of 4,312,275 shares. The stock had previously closed at $23.28.
Specifically, Director Joseph P. Slattery sold 5,200 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the completion of the transaction, the director directly owned 1,467 shares of the company’s stock, valued at approximately $31,980.60. The trade was a 78.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Replimune Group in a report on Wednesday, November 4th. Wolfe Research raised Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Finally, Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.
Replimune Group Stock Performance
The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11. The firm has a 50-day moving average of $14.63 and a 200 day moving average of $9.97.
Replimune Group (NASDAQ:REPL – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. Equities research analysts expect that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.
Institutional Trading of Replimune Group
Several hedge funds have recently added to or reduced their stakes in REPL. Russell Investments Group Ltd. raised its holdings in shares of Replimune Group by 37.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 81,955 shares of the company’s stock valued at $1,085,000 after buying an additional 22,316 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Replimune Group in the 3rd quarter worth approximately $64,000. Vise Technologies Inc. purchased a new stake in Replimune Group in the third quarter worth approximately $163,000. China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 30.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after buying an additional 4,050 shares in the last quarter. Finally, Maxi Investments CY Ltd purchased a new stake in Replimune Group in the third quarter worth approximately $556,000. Institutional investors own 92.53% of the company’s stock.
About Replimune Group
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Further Reading
- Five stocks we like better than Replimune Group
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
